The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir

Antiviral Research

Volumn 91, Issue 3, 2011, Pages 292-295

  Canducci, Filippo ^d,e   Ceresola, Elisa Rita ^d   Saita, Diego ^d   Al Abed, Yousef ^b   Garotta, Gianni ^c   Clementi, Massimo ^d   Nicoletti, Ferdinando ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c GaNiAl Immunotherapeutics   (United States)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Drug resistance; Genetic barrier; Protease inhibitors; Saquinavir; Toxicity

Indexed keywords

SAQUINAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; BIOASSAY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; MUTANT; MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS MUTANT; VIRUS REPLICATION; WILD TYPE;

CD4-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; DNA PRIMERS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MUTAGENESIS, SITE-DIRECTED; SAQUINAVIR;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79960693823     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.07.001     Document Type: Article

References (18)

1. Boeri E., Gianotti N., Canducci F., Hasson H., Giudici B., Castagna A., Lazzarin A., Clementi M. Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure. AIDS Res. Hum. Retroviruses 2003, 19:1151-1153.
2. Boesecke C., Cooper D.A. Toxicity of HIV protease inhibitors: clinical considerations. Curr. Opin. HIV AIDS 2008, 3:653-659.
3. Brun-Vézinet F., Ingrand D., Deforges L., Gochi K., Ferchal F., Schmitt M.P., Jung M., Masquelier B., Aubert J., Buffet-Janvresse C., Fleury H. HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase. J. Virol. Methods 1992, 37:177-188.
4. Canducci F., Marinozzi M.C., Sampaolo M., Boeri E., Spagnuolo V., Gianotti N., Castagna A., Paolucci S., Baldanti F., Lazzarin A., Clementi M. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. J. Antimicrob. Chemother. 2010, 65:425-433.
5. Fernandez-Montero J.V., Barreiro P., Soriano V. HIV protease inhibitors: recent clinical trials and recommendations on use. Expert Opin. Pharmacother. 2009, 10:1615-1629.
6. Hruz P.W. HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models. Curr. Opin. HIV AIDS 2008, 3:660-665.
7. Johnson V.A., Brun-Vézinet F., Clotet B., Günthard H.F., Kuritzkes D.R., Pillay D., Schapiro J.M., Richman D.D. Update of the drug resistance mutations in HIV-1. Top. HIV Med. 2008, 16:138-145.
8. Johnson V.A., Brun-Vézinet F., Clotet B., Günthard H.F., Kuritzkes D.R., Pillay D., Schapiro J.M., Richman D.D. Update of the drug resistance mutations in HIV-1: December 2009. Top. HIV Med. 2009, 17:138-145.
9. Kempf D.J., Marsh K.C., Kumar G., Rodrigues A.D., Denissen J.F., McDonald E., Kukulka M.J., Hsu A., Granneman G.R., Baroldi P.A., Sun E., Pizzuti D., Plattner J.J., Norbeck D.W., Leonard J.M. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 1997, 41:654-660.
10. Maksimovic-Ivanic D., Mijatovic S., Miljkovic D., Harhaji-Trajkovic L., Timotijevic G., Mojic M., Dabideen D., Cheng K.F., McCubrey J.A., Mangano K., Al-Abed Y., Libra M., Garotta G., Stosic-Grujicic S., Nicoletti F. The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt. Mol. Cancer Ther. 2009, 8:1169-1178.
11. Martinez-Cajas J.L., Pant-Pai N., Klein M.B., Wainberg M.A. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev. 2008, 10:212-223.
12. Menzo S., Monachetti A., Balotta C., Corvasce S., Rusconi S., Paolucci S., Baldanti F., Bagnarelli P., Clementi M. Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors. AIDS 2003, 17:663-671.
13. Paolucci S., Baldanti F., Zavattoni M., Comolli G., Labò N., Menzo S., Clementi M., Gerna G. Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naive and HAART-experienced HIV-infected patients. J. Antimicrob. Chemother. 2003, 51:135-139.
14. Ribera E., Curran A. Double-boosted protease inhibitor antiretroviral regimens: what role?. Drugs 2008, 68:2257-2267.
15. Santos A.F., Abecasis A.B., Vandamme A.M., Camacho R.J., Soares M.A. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G. J. Antimicrob. Chemother. 2009, 63:593-599.
16. Schütt M., Zhou J., Meier M., Klein H.H. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells. J. Endocrinol. 2004, 183:445-454.
17. Shen L., Peterson S., Sedaghat A.R., McMahon M.A., Callender M., Zhang H., Zhou Y., Pitt E., Anderson K.S., Acosta E.P., Siliciano R.F. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 2008, 14:762-766.
18. Wensing A.M., van Maarseveen N.M., Nijhuis M. Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res. 2010, 85:59-74.